At a glance
Sansanima joined the o2h Ventures chaitime portfolio pitch day at the Cambridge HQ, hosted by Sunil Shah. The event brought together promising early stage biotech companies to share progress with investors and partners.
What we presented
Our team outlined how Sansanima is replacing animal testing in industrial processes with fully physiological, cell based assays. The platform focuses first on clostridial neurotoxin products such as tetanus and botulinum, with a pathway to wider use across biologics. We also highlighted regulatory validation work, patent filings in major markets, and collaborations with global vaccine and toxin producers.
Why it matters
Human relevant assays provide specific, sensitive, and reproducible readouts that improve quality control and reduce reliance on animals. This supports safer products, clearer decisions, and better scalability for manufacturers and regulators.
Thank you
Thank you to Sunil Shah and the o2h Ventures team for the invitation and an engaging afternoon.